Aciclovir

drugbox

---

---

IUPAC_name = 2-amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one
synonyms = acycloguanosine
CAS_number = 59277-89-3
ChemSpiderID = 1945
ATC_prefix = J05
ATC_suffix = AB01
ATC_supplemental = ATC|D06|BB03 ATC|S01|AD03
PubChem = 2022
DrugBank = APRD00567
C=8 | H=11 | N=5 | O=3
molecular_weight = 225.21 g/mol
melting_point = 256.5
bioavailability = 10–20% (oral)
protein_bound = 9–33%
metabolism = Viral thymidine kinase
elimination_half-life = 2.2–20 hours
excretion = Renal
pregnancy_category = B3 (Au), B (U.S.)
legal_status = unscheduled/S4 (Au), POM (UK)
routes_of_administration = Intravenous, oral, topical

Aciclovir (INN) (pronEng|eɪˈsaɪkloʊvɪr) or acyclovir (USAN, former BAN), chemical name acycloguanosine, is a guanosine analogue antiviral drug, marketed under trade names such as "Cyclovir", "Herpex", "Acivir", "Zovirax" and "Zovir" (GSK). One of the most commonly-used antiviral drugs, it is primarily used for the treatment of herpes simplex virus infections, as well as in the treatment of herpes zoster (shingles).

Aciclovir was seen as the start of a new era in antiviral therapy, as it is extremely selective and low in cytotoxicity. Pharmacologist Gertrude B. Elion was awarded the 1988 Nobel Prize in Medicine, partly for the development of aciclovir.

Pharmacology

Mechanism of action

Aciclovir differs from previous nucleoside analogues in that it contains only a partial nucleoside structure: the sugar ring is replaced by an open-chain structure. It is selectively converted into acyclo-guanosine monophosphate (acyclo-GMP) by viral thymidine kinase, which is far more effective (3000 times) in phosphorylation than cellular thymidine kinase. Subsequently, the "monophosphate" form is further phosphorylated into the active "triphosphate" form, acyclo-guanosine triphosphate (acyclo-GTP), by cellular kinases. Acyclo-GTP is a very potent inhibitor of viral DNA polymerase; it has approximately 100 times greater affinity for viral than cellular polymerase. As a substrate, acyclo-GMP is incorporated into viral DNA, resulting in chain termination. It has also been shown that viral enzymes cannot remove acyclo-GMP from the chain, which results in inhibition of further activity of DNA polymerase. Acyclo-GTP is fairly rapidly metabolised within the cell, possibly by cellular phosphatases.

In sum, aciclovir can be considered a prodrug: it is administered in an inactive (or less active form) and is metabolised into a more active species after administration.

Microbiology

Aciclovir is active against most species in the herpesvirus family. In descending order of activity:O'Brien JJ, Campoli-Richards DM. Aciclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989;37(3):233-309. PMID 2653790]
*Herpes simplex virus type I (HSV-1)
*Herpes simplex virus type II (HSV-2)
*Varicella zoster virus (VZV)
*Epstein-Barr virus (EBV)
*Cytomegalovirus (CMV) -- least activity

Activity is predominantly against HSV, and to a lesser extent VZV. It is only of limited efficacy against EBV and CMV. It is inactive against latent viruses in nerve ganglia.

To date, resistance to aciclovir has not been clinically significant. Mechanisms of resistance in HSV include deficient viral thymidine kinase; and mutations to viral thymidine kinase and/or DNA polymerase, altering substrate sensitivity.Sweetman S, editor. Martindale: The complete drug reference. 34th ed. London: Pharmaceutical Press; 2004. ISBN 0-85369-550-4]

Pharmacokinetics

Aciclovir is poorly water soluble and has poor oral bioavailability (10–20%), hence intravenous administration is necessary if high concentrations are required. When orally administered, peak plasma concentration occurs after 1–2 hours. Aciclovir has a high distribution rate, only 30% is protein-bound in plasma. The elimination half-life of aciclovir is approximately 3 hours. It is renally excreted, partly by glomerular filtration and partly by tubular secretion.

The poor oral bioavailability may also be improved by administering Valaciclovir, which has a oral bioavailability of about 55%. Valaciclovir is then converted to Aciclovir by esterases via hepatic first-pass metabolism.

Clinical use

Indications

Aciclovir is indicated for the treatment of HSV and VZV infections, including:Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3]
* Genital herpes simplex (treatment and prophylaxis)
* Herpes simplex labialis (cold sores)
* Herpes zoster (shingles)
* Acute chickenpox in immunocompromised patients
* Herpes simplex encephalitis
* Acute mucocutaneous HSV infections in immunocompromised patients
* Herpes simplex keratitis (ocular herpes)
* Herpes simplex blepharitis (not to be mistaken with ocular herpes)
* Bell's Palsy

It has been claimed that the evidence for the effectiveness of topically applied cream for recurrent labial outbreaks is weak. [cite journal
author=Graham Worrall
title=Evidence for efficacy of topical aciclovir in recurrent herpes labialis is weak
journal=BMJ | year=1996 | month=6 Jul | volume=313 | pages=46
url=http://www.bmj.com/cgi/content/full/313/7048/46/a - Letter] An earlier review of scientific literature showed that there is some effect in reducing the number and duration of lesions if aciclovir is applied at an early stage of an outbreak. [cite journal | author=Graham Worrall | title=Acyclovir in recurrent herpes labialis | journal=BMJ | year=1996 | month=6 Jan | volume=312 | pages=6 | url=http://www.bmj.com/cgi/content/full/312/7022/6 | pmid=8555890 - Editorial] However, it was concluded that oral therapy for episodes is inappropriate for most non-immunocompromised patients based on costs and benefits, presumably in countries where aciclovir is only available on prescription. It was concluded that there is evidence for an oral prophylactic role in preventing recurrences.

Dosage forms

Aciclovir is commonly marketed as tablets (200mg, 400mg, 800mg and 1 gram), topical cream (5%), intravenous injection (25 mg/mL) and ophthalmic ointment (3%). Cream preparations are used primarily for labial herpes simplex. The intravenous injection is used when high concentrations of aciclovir are required. The ophthalmic ointment preparation is only used for herpes simplex keratitis.

Adverse effects

ystemic therapy

Common adverse drug reactions (≥1% of patients) associated with systemic acyclovir therapy (oral or IV) include: nausea, vomiting, diarrhea and/or headache. In high doses, hallucinations have been reported. Infrequent adverse effects (0.1–1% of patients) include: agitation, vertigo, confusion, dizziness, oedema, arthralgia, sore throat, constipation, abdominal pain, rash and/or weakness. Rare adverse effects (<0.1% of patients) include: coma, seizures, neutropenia, leukopenia, crystalluria, anorexia, fatigue, hepatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis and/or anaphylaxis.

Additional common adverse effects, when acyclovir is administered IV, include encephalopathy (1% of patients) and injection site reactions. The injection formulation is alkaline (pH 11), and extravasation may cause local tissue pain and irritation. Renal impairment has been reported when acyclovir is given in large, fast doses intravenously, due to the crystallisation of acyclovir in the kidneys.

Topical therapy

Acyclovir topical cream is commonly associated (≥1% of patients) with: dry or flaking skin and/or transient stinging/burning sensations. Infrequent adverse effects include erythema and/or itch.

When applied to the eye, acyclovir is commonly associated (≥1% of patients) with transient mild stinging. Infrequently (0.1–1% of patients), ophthalmic aciclovir is associated with superficial punctate keratitis and/or allergic reactions.

Toxicity

Since acyclovir can also be incorporated into cellular DNA, it is a chromosome mutagen, therefore, its use should be avoided during pregnancy. Fact|date=May 2008 However it has not been shown to cause any teratogenic or carcinogenic effects. Fact|date=May 2008 The acute toxicity (LD₅₀) of aciclovir when given orally is greater than 1 g/kg, due to its low oral bioavailability. Fact|date=May 2008

Footnotes

Further reading

* Harvey Stewart C. in Remington’s Pharmaceutical Sciences 18th edition: (ed. Gennard, Alfonso R.) Mack Publishing Company, 1990. ISBN 0-912734-04-3.
* Huovinen P., Valtonen V. in Kliininen Farmakologia (ed. Neuvonen et al.). Kandidaattikustannus Oy, 1994. ISBN 951-8951-09-8.
* Périgaud C., Gosselin G., Imbach J. -L.: Nucleoside analogues as chemotherapeutic agents: a review. Nucleosides and nucleotides 1992; 11(2-4)
* Rang H.P., Dale M.M., Ritter J.M.: Pharmacology, 3^rd edition. Pearson Professional Ltd, 1995. 2003 (5th) edition ISBN 0-443-07145-4; 2001 (4th) edition ISBN 0-443-06574-8; 1990 edition ISBN 0-443-03407-9.

See also

Valaciclovir